Add To Watchlist
Share URL
About The Company
CEO
Mr. Mark Joseph Enyedy
Market Cap
8.73 Billion USD
Sector
Healthcare
Website
https://www.immunogen.comLast Update
2/22/2024, 12:00:00 PM
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer.
Read More
Overview
Value
1
Growth
41
Health
64
Management
62
Analyst Opinion
77
Total
46
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Has a low level of debt
- Low risk of bankruptcy
- Has strong financial health
- Liked by analysts
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Income is not covering expenditure and investment
- There is a history of diluting shareholders
- No margin of safety at their current market price
- Disliked by Twitter users
- Dividend could be at risk
Market Peers
IMGN
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-97.65%
Revenue Growth (5 Year Average)
16.21%
Ratings Consensus
Buy
Share Buybacks
-3.65%
Dividend Yeild (TTM)
0.00%
Valuation
Value Score
1
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 0.5 USD ✘
Current Price: 31.2 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-2.29%
PE/Earnings Growth
N/A
Price/Book
15.54x
Growth
Growth Score
41
- ✔ 5 Year Average Revenue growth of 16.21% is higher than the market average (10.97%)
- ✔ Revenue growth has improved this yeara
- ✔ Earnings growth has improved this year
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Earnings growth of 7.14% is lower than the market average (14.48%)
- ✘ 5 Year Average Free Cashflow growth of 0.42% is lower than the market average (12.35%)
Revenue Growth
16.21%
Earnings Growth
7.14%
Cashflow Growth
0.42%
Health
Health Score
64
Altman Z Score
18.10
Piostroski Score
3.00
Debt/Equity
0.13x
Current Assets/Liabilities
5.67x
Free Cashflow/Total Debt
0.02x
Debt/Capital
0.09x
Dividend
Secure Dividend Score
0
- ✔ Long term dividend payout ratio of 0.00% is considered good
- ✔ Payout ratio (TTM) of 0.00% is lower than the average (40%)
- ✔ Dividends have shown growth over the last 5 years
- ✔ Spending a lower percentage of their income on dividends than last 5 years
- ✘ Dividend yeild of 0.00% is less than the market average (1.85%)
- ✘ Very unsafe
Dividend Yeild
0.00%
Dividend Growth
0.00%
Payout Ratio (Earnings)
0.00%
Payout Ratio (Cashflow)
0.00%
Management
Management Score
62
Average Buybacks/Dilution
-3.65%
Recent Buybacks/Dilution
-2.86%
5 Year Price Volitility
74.59%
Return On Assets
3.40%
Return On Capital Employed
3.69%
Return On Equity
4.97%
Return On Free Cashflow
N/A
Return On Investments
N/A
Analysts
Analyst Opinion
77
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
ImmunoGen, Inc.
Currency
USD
Beta
0.999316
Vol Avg
8284095
Ceo
Mr. Mark Joseph Enyedy
Cik
0000855654
Cusip
45253H101
Exchange
NASDAQ Global Select
Full Time Employees
277
Industry
Biotechnology
Sector
Healthcare
Ipo Date
1989-11-17
Address
830 Winter Street
City
Waltham
State
MA
Country
US
Zip
02451-1477
Phone
781 895 0600
Analysis Last Updated
2/22/2024, 12:00:00 PM
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
28
Twitter Sentiment
0.00
Stocktwits Sentiment
56.00